Skip to main content
BIOE
OTC Life Sciences

Bio Essence Q3 Swings to $150K Loss; Going Concern and Weak Controls Reaffirmed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.47
Mkt Cap
$25.29M
52W Low
$0.051
52W High
$10.809
52W Position info
822% above low
Off High info
96% below high
Rel. Volume
Market data snapshot near publication time

BIOE has more than doubled off its 52-week low of $0.051.

Summary

Bio Essence posted a $150,458 net loss for Q3 2026 after a profitable first half, while repeating going-concern doubt, disclosing ineffective internal controls, and holding just $201,511 of cash against $1.65 million of current liabilities.


Key Events · Earnings and Guidance · BIOE

  • Q3 Swings to $150,458 Net Loss

    Three-month revenue rose 85.0% to $253,020, but G&A jumped 268.9% to $298,286 (including $174,942 of new intangible amortization), producing a $150,458 net loss versus $12,998 of income in Q3 2025.

  • Nine-Month Profit, Revenue Up 270%

    Nine-month revenue reached $1,548,268 versus $418,112, and net income was $324,992 versus a $132,890 loss, with gross profit of $928,775 (60.0% margin).

  • Going Concern Doubt Reaffirmed

    Accumulated deficit of $9,228,081 and working capital deficit of $1,374,178 keep substantial doubt about the ability to continue as a going concern; management estimates $1.2 million of cash is needed for the next 12 months.

  • Controls Concluded Not Effective

    Management concluded disclosure controls and internal control over financial reporting were not effective as of September 30, 2026.


Analysis · BIOE · Life Sciences

The nine-month picture looks strong — revenue of $1,548,268, up 270.3%, and net income of $324,992 versus a $132,890 loss a year ago — but the third quarter alone reversed: a $150,458 net loss against $12,998 of income in Q3 2025, as general and administrative expense jumped 268.9% to $298,286, largely from $174,942 of amortization on the newly acquired MediFlow software. Against that, the company still carries a $9,228,081 accumulated deficit and a $1,374,178 working capital deficit, holds only $201,511 of cash against $1,653,097 of current liabilities, and says it needs about $1.2 million for the next 12 months. Management repeats that these conditions raise substantial doubt about its ability to continue as a going concern, and both disclosure controls and internal control over financial reporting were concluded not effective. A further 10,000,000 shares (contractual $0.10 each) are owed to Zhituo only if the AI platform development is completed and accepted, with milestone dates running to December 15, 2026 — a real overhang if it lands.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIOE was trading at $0.47 on OTC in the Life Sciences sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $0.05 to $10.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIOE - Latest Insights

BIOE
Oct 21, 2026, 10:41 AM EDT
Filing Type: PRE 14C
Importance Score:
7
Price at Filing: $0.4201
Real-time Price: $0.470 info
Change: +$0.0499 (+12%) info
Market Cap: $25.29M info
BIOE
Aug 14, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.250
Real-time Price: $0.470 info
Change: +$0.220 (+88%) info
Market Cap: $25.29M info
BIOE
May 19, 2026, 4:01 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.300
Real-time Price: $0.470 info
Change: +$0.170 (+57%) info
Market Cap: $25.29M info
BIOE
May 15, 2026, 2:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.380
Real-time Price: $0.470 info
Change: +$0.090 (+24%) info
Market Cap: $25.29M info
BIOE
Apr 23, 2026, 8:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.450
Real-time Price: $0.470 info
Change: +$0.020 (+4%) info
Market Cap: $25.29M info